Transforming Pediatric Cholestatic Liver Disease: New Insights into Biliary Atresia and Genetic Cholangiopathies
Nov
2026
Description
This session presents genetic and mechanistic insights into biliary atresia and pediatric cholangiopathies, alongside emerging therapies and outcomes following Kasai portoenterostomy.
Presentations
2:00 PM
- 2:15 PM
Convention Center - Bluebird Ballroom 2ABC
A phase 2-ready ASK1 inhibitor suppresses post-obstructive cholestatic inflammation and fibrosis in experimental biliary atresia
Pranavkumar Shivakumar, MPharm, PhD (Tech.), FAASLD | Abstract Presenter
2:15 PM
- 2:30 PM
Convention Center - Bluebird Ballroom 2ABC
Fibronectin–integrin α5β1 crosstalk is a therapeutic epithelial–immune axis in biliary atresia
Wenqi Li, MB | Abstract Presenter
2:30 PM
- 2:45 PM
Convention Center - Bluebird Ballroom 2ABC
ADJUVANT GRANULOCYTE COLONY-STIMULATING FACTOR AFTER KASAI PORTOENTEROSTOMY FOR BILIARY ATRESIA: A PHASE 2 RANDOMIZED CONTROLLED TRIAL
Anh - Hoa Pham Nguyen, MD | Abstract Presenter
2:45 PM
- 3:00 PM
Convention Center - Bluebird Ballroom 2ABC
Early Timepoints are Critical in Biliary Atresia: Results from Prospectively Following 831 Infants Receiving the Kasai Portoenterostomy
Sanjiv Harpavat, MD, PhD | Abstract Presenter
3:00 PM
- 3:15 PM
Convention Center - Bluebird Ballroom 2ABC
Genotypic Spectrum and Clinical Outcomes of Genetic Liver Diseases across Asia-Pacific Countries: The ANGELD Study
Huey-Ling Chen, MD, PhD, FAASLD | Abstract Presenter
3:15 PM
- 3:30 PM
Convention Center - Bluebird Ballroom 2ABC
Genetic analyses of 1,732 biliary atresia cases identify novel etiologic risk genes in developmental, ciliary, and cholestatic injury pathways
Ronnie Y Li, PhD, | Abstract Presenter
